Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

URSODIOL

All products: Limited Use (codes 273, 534)

PMS-Ursodiol C · DIN 02273497 · 250mg · tablet

Limited Use — Reason for Use code 273, 534 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 273, 534 required
Write on scriptLU code 273, 534 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 273, 534
Reason for Use code 273 For the treatment of primary biliary cirrhosis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 534 For the treatment of primary sclerosing cholangitis. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ursodiol C · DIN 02273497 Manufacturer: Pharmascience Inc.; listing date 2007-04-02 Health Canada: Marketed since 2006-05-01 · brand PMS-URSODIOL C · ATC A05AA02 URSODEOXYCHOLIC ACID · form Tablet · route Oral · ingredients URSODIOL 250 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Ursodiol C: Formulary list price $0.3818/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3818 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75898 · Verify on the e-Formulary ↗ (DIN 02273497)

Source record
DIN 02273497: PMS-Ursodiol C Raw flags: sec12=Y, sec3=Y Item: 920000308; group id 973; item number 2306; lccId 00141; manufacturer id PMS Source form: Tab; strength: 250mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3818; ministry $0.3818 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02273497 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75898
Interchangeable products
AG-Ursodiol · DIN 02505363 · $0.3818 GLN-Ursodiol · DIN 02426900 · $0.3818 Jamp-Ursodiol · DIN 02472392 · $0.3818 NRA-Ursodiol · DIN 02544032 · $0.3818 Urso · DIN 02238984 · not recorded Ursodiol C · DIN 02515520 · $0.3818
Shortage status: resolved shortage (ended 2024-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02273497
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-URSODIOL C (ursodiol tablets, USP), also known as ursodeoxycholic acid (UDCA) is indicated for: • the management of cholestatic liver diseases, such as primary biliary cirrhosis (PBC). 1.1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00072506.PDF PM date: SEP 11, 2023 Source product: PMS-URSODIOL C; DIN 02273497; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.